Humanoid's $152m Round Recapitalises A Business With £50.5m Of Founder Loans

Humanoid's $152 million Series A does more than fund robot production. It recapitalises a company that ended 2025 with £43.5 million of net liabilities and £50.5 million owed to its founder, Artem Sokolov.

Those figures appear in SKL Robotics Ltd's audited 2025 accounts. SKL Robotics is the UK company behind Humanoid. Its auditor reported a material uncertainty related to going concern after a £40.2 million loss, although the audit opinion was not modified.

The financing risk was concentrated in one person. Sokolov advanced £45.0 million during 2025, taking his total loans to £50.5 million by year end. A later shareholder filing indicates that he also preserved majority ordinary-equity exposure through the latest visible allotment before the Series A announcement.

That makes the round a shift in Humanoid's funding base, not just a valuation milestone. Institutional investors are now financing the path to production behind a balance sheet that had relied on its founder as both owner and lender.

The 2025 Accounts Reframe The Unicorn Round

Humanoid announced on 21 July that it had raised $152 million at a $1.35 billion post-money valuation. The round was led by Prime Movers Lab, with Schaeffler, Bosch, Fubon Financial Holding Venture Capital and Aglaé Ventures participating. Humanoid said the financing brought its total funding to $270 million.

Reuters independently reported the amount, valuation and investor group. Most coverage therefore focused on Humanoid becoming a robotics unicorn only two years after it was founded.

The audited accounts show the starting point from which that valuation was reached.

The comparison is historical, not a post-round liquidity estimate. The accounts closed on 31 December 2025, while Humanoid announced the Series A almost seven months later. Their value is that they identify what the new money is entering behind.

The auditor drew attention to the £40.2 million loss and the £43.5 million net-liability position. Together with other conditions in the accounts, those figures created material uncertainty about the company's ability to continue as a going concern. The directors nevertheless prepared the accounts on a going-concern basis, and the auditor said that treatment was appropriate.

The Founder Was Both Lender And Majority Owner

The notes to the accounts identify Sokolov as Humanoid's sole shareholder and ultimate controlling party at the 2025 balance-sheet date. His loans were unsecured, carried interest of 0.1% a year and had a fixed repayment date.

That low interest rate shows the loans were not priced like conventional high-risk growth debt. Sokolov supplied low-cost, unsecured founder capital while retaining the equity upside if Humanoid succeeded.

The next filings show how much of that upside remained visible as outside capital arrived. A confirmation statement dated 10 July names Sokolov with 20.4 million ordinary shares. The company's ordinary capital at that point was 23,305,100 shares.

Four days later, a return of allotment recorded 15,031,254 new ordinary shares and one S ordinary share. That took ordinary capital to 38,336,354 shares.

The four-day bridge supports a precise but conditional conclusion. If Sokolov's disclosed holding did not change between 10 and 14 July, he retained 53.21% of the ordinary shares after the allotment.

The filing does not map the new shares to Prime Movers Lab, Bosch, Schaeffler, Fubon or Aglaé. It also should not be used to claim that every dollar of the announced round had appeared in the UK register by 14 July. The durable finding is narrower: the visible dilution still left Sokolov with a majority of the ordinary class.

One Share Can Stop Every Resolution

The 14 July allotment also created one S ordinary share. Numerically, it is immaterial. Legally, it has an unusually powerful consent right.

No ordinary or special resolution is valid unless the S-share holder votes in favour or gives written consent. The share otherwise participates in dividends alongside ordinary and Series A shares, while ranking behind Series A preferences on a return of capital.

The holder is not identified in the public allotment. The share therefore prevents a clean conclusion that ordinary-share majority alone equals complete shareholder control. Humanoid's next articles and confirmation statement need to connect that governance right to a named holder.

Companies House listed new articles and resolutions on 22 July, including resolutions on allotments, pre-emption rights and option-scheme limits. At the time of publication, those documents were still being processed.

The Money Is Also For Manufacturing

The balance-sheet reading does not erase the round's operating purpose. Humanoid says the money will fund its next robot platform, commercial deployments, mass manufacturing of wheeled robots and development of its KinetIQ artificial-intelligence software.

Bosch brings more than capital. Reuters reported that it will serve as Humanoid's contract-manufacturing partner and provide expertise in hardware design, production and supply chains. Schaeffler is both an investor and a prospective customer under an agreement for planned deployment of thousands of robots at manufacturing sites.

Those relationships make strategic sense for a company moving from research and prototypes toward industrial production. Building robots at scale requires engineering, inventory, manufacturing capacity and customer-site deployment before recurring economics are proven.

The accounts put a number on how founder-dependent that build had been. Sokolov's loans increased from £4.75 million to £50.53 million during 2025. The £45.02 million advanced in one year represented 89% of the closing loan balance.

Institutional capital can diversify that burden and finance a larger operating plan. It can also improve the position of an existing lender by putting more capital underneath the business. The public filings stop before the decisive step: they do not say whether Sokolov's loans were repaid, converted into shares, subordinated to new investors or left outstanding on their existing terms.

The Round Preserves Both Upside And An Open Creditor Question

Before the Series A, Sokolov carried two distinct exposures. As lender, he had a £50.5 million claim against a company with £43.5 million of net liabilities. As shareholder, he owned most of the equity and would capture most of the upside if Humanoid reached commercial scale.

The July filings indicate that the equity exposure remained substantial. The round therefore appears to reduce concentration in Humanoid's funding without removing Sokolov from the centre of its economics.

The sequence changes the central investment question. The $152 million headline establishes the scale of the new capital. The accounts and shareholder filings establish who carried the risk before it arrived and who appeared to keep the upside afterward.

Humanoid's next accounts must show what happened to the £50.5 million founder-loan balance. Its next confirmation statement and available articles must show who received the new shares and who holds the S-share veto.

Until those records arrive, the strongest conclusion is also the narrowest. Humanoid's institutional round recapitalised a founder-financed robotics company, while the visible ordinary-share math left the founder with a majority stake and the treatment of his creditor claim unresolved.